Proteonomix has entered into an agreement with Numoda Corp. for global clinical trial technologies and services. In August, the FDA granted permission to Proteonomix to initiate a Phase I clinical trial to evaluate UMK-121 in patients with end-stage liver disease (ESLD). Numoda provides clinical trial information and logistics services.

“Our engagement of Numoda is an important step in effectively and efficiently advancing the development of our proprietary therapeutics,” said Proteonomix chief technology officer Steven Byle. “Numoda has a proven, innovative approach for assisting life sciences companies like Proteonomix to move through the clinical development process. We anticipate collaborating with the Numoda team on the Phase I clinical trial with our mobilization technology UMK-121 in patients with ESLD.”